Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company's current programs address pathogenic processes selectively, rather than aiming to broadly eliminate pathogens, potentially allowing Arsanis to address critical infections without contributing to the problem of antimicrobial resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is being evaluated in a Phase 2 clinical study for the prevention of Staphylococcus aureus pneumonia in high-risk patients.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/26/17	$45,500,000	Series D	Alexandria Real Estate Equities Bill & Melinda Gates Foundation EMBL Ventures NeoMed Management OrbiMed Advisors Polaris Partners Stephen Kellen Foundation SV Health Investors	undisclosed